Salud financiera de hoja de balance de Kiniksa Pharmaceuticals
Salud financiera controles de criterios 4/6
Kiniksa Pharmaceuticals tiene un patrimonio de los accionistas total de $438.8M y una deuda total de $12.3M, lo que sitúa su ratio deuda-patrimonio en 2.8%. Sus activos y pasivos totales son $526.3M y $87.5M respectivamente.
Información clave
2.8%
Ratio deuda-patrimonio
US$12.26m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$206.37m |
| Patrimonio | US$438.84m |
| Total pasivo | US$87.48m |
| Activos totales | US$526.32m |
Actualizaciones recientes sobre salud financiera
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17Recent updates
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Nov 30Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
Nov 16Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($276.3M) de KNSA superan a sus pasivos a corto plazo ($63.7M).
Pasivo a largo plazo: Los activos a corto plazo de KNSA ($276.3M) superan a sus pasivos a largo plazo ($23.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: KNSA tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de KNSA ha crecido de 0% a 2.8% en los últimos 5 años.
Cobertura de la deuda: La deuda de KNSA está bien cubierta por el flujo de caja operativo (108.5%).
Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de KNSA sobre su deuda están bien cubiertos por el EBIT.